1,655
Views
7
CrossRef citations to date
0
Altmetric
Letter to the Editor

Uric acid levels are independent of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease: A reappraisal of the role of S. cerevisiae in this setting

ORCID Icon, ORCID Icon, , , , , & show all
Pages 1224-1229 | Received 08 May 2018, Accepted 28 Jun 2018, Published online: 08 Aug 2018

References

  • Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec 23;390(10114):2769–2778. PubMed PMID: 29050646.
  • Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of Inflammatory Bowel diseases and therapeutic approaches. Gastroenterology. 2017 Feb;152(2):327–339 e4. PubMed PMID: 27769810; PubMed Central PMCID: PMCPMC5511756.
  • Rieder F, Hahn P, Finsterhoelzl L, et al. Clinical utility of anti-glycan antibodies in pediatric Crohn’s disease in comparison with an adult cohort. Inflamm Bowel Dis. 2012 Jul;18(7):1221–1231. PubMed PMID: 22147427.
  • Siegel CA, Horton H, Siegel LS, et al. A validated web-based tool to display individualised Crohn’s disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther. 2016 Jan;43(2):262–271. PubMed PMID: 26567467.
  • Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016 Jun;43(12):1300–1310. PubMed PMID: 27117843.
  • Chiaro TR, Soto R, Zac Stephens W, et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med. 2017 Mar 08;9(380). PubMed PMID: 28275154.
  • Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology. 2006 Aug;131(2):366–378. PubMed PMID: 16890590.
  • Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998 Jun;42(6):788–791. PubMed PMID: 9691915; eng.
  • Poulain D, Sendid B, Fajardy I, et al. Mother to child transmission of anti-Saccharomyces cerevisiae mannan antibodies (ASCA) in non-IBD families. Gut. 2000;47(6):870–871. PubMed PMID: 11186432.
  • Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol. 1996 Mar;3(2):219–226. PubMed PMID: 8991640; eng.
  • Wild R, Kowal J, Eyring J, et al. Structure of the yeast oligosaccharyltransferase complex gives insight into eukaryotic N-glycosylation. Science. 2018 Feb 2;359(6375):545–550. PubMed PMID: 29301962.
  • Dotan N, Altstock RT, Schwarz M, et al. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus. 2006;15(7):442–450. PubMed PMID: 16898180.
  • Poulain D, Sendid B, Standaert-Vitse A, et al. Yeasts: neglected pathogens. Dig Dis. 2009;27 Suppl 1:104–110. PubMed PMID: 20203505.
  • Barta Z, Csipo I, Szabo GG, et al. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn’s disease and celiac disease. World J Gastroenterol. 2003 Oct;9(10):2308–2312. PubMed PMID: 14562398; eng.
  • Kvehaugen AS, Aasbrenn M, Farup PG. Anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a cross-sectional study. BMC Obes. 2017;4:28. PubMed PMID: 28725447; PubMed Central PMCID: PMCPMC5512824.
  • Tsushima Y, Nishizawa H, Tochino Y, et al. Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem. 2013 Sep 20;288(38):27138–27149. PubMed PMID: 23913681; PubMed Central PMCID: PMCPMC3779712.
  • Salamati S, Martins C, Kulseng BB. yeast (Saccharomycescerevisiae) antigen in obese and normal weight subjects. Clin Obes. 2015 Feb;5(1):42–47. PubMed PMID: 25611585.
  • Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017 Apr 3;8(3):352–358. PubMed PMID: 27736307; PubMed Central PMCID: PMCPMC5411236.
  • Calderone R, Clancy C. Candida and Candidiasis. 2nd ed. Washington DC: ASM Press; 2012.
  • Huseyin CE, Rubio RC, O’Sullivan O, et al. The fungal frontier: a comparative analysis of methods used in the study of the human Gut mycobiome. Front Microbiol. 2017;8:1432. PubMed PMID: 28824566; PubMed Central PMCID: PMCPMC5534473.
  • Kohler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med. 2014 Nov 3;5(1):a019273. PubMed PMID: 25367975; PubMed Central PMCID: PMCPMC4292074.
  • de Llanos R, Fernandez-Espinar MT, Querol A. A comparison of clinical and food Saccharomyces cerevisiae isolates on the basis of potential virulence factors. Antonie Van Leeuwenhoek. 2006 Oct;90(3):221–231. PubMed PMID: 16871421.
  • de Llanos R, Llopis S, Molero G, et al. In vivo virulence of commercial Saccharomyces cerevisiae strains with pathogenicity-associated phenotypical traits. Int J Food Microbiol. 2011 Jan 5;144(3):393–399. PubMed PMID: 21081253.
  • Jawhara S, Habib K, Maggiotto F, et al. Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractions. PLOS ONE. 2012;7(7):e40648.
  • Anoop V, Rotaru S, Ps S, et al. Review of current methods for characterizing virulence and pathogenicity potential of industrial Saccharomyces cerevisiae strains towards humans. FEMS Yeast Res. 2015 Sep;15(6). PubMed PMID: 26195617. DOI:10.1093/femsyr/fov057.
  • Pfliegler WP, Boros E, Pazmandi K, et al. Commercial strain-derived clinical Saccharomyces cerevisiae can evolve new phenotypes without higher pathogenicity. Mol Nutr Food Res. 2017 Nov;61(11). PubMed PMID: 28731263. DOI: 10.1002/mnfr.201601099.
  • Bougnoux ME, Diogo D, Francois N, et al. Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J Clin Microbiol. 2006 May;44(5):1810–1820. PubMed PMID: 16672411; PubMed Central PMCID: PMCPMC1479199.
  • Huang G, Wang H, Chou S, et al. Bistable expression of WOR1, a master regulator of white-opaque switching in Candida albicans. Proc Natl Acad Sci U S A. 2006 Aug 22 103(34):12813–12818. PubMed PMID: 16905649; PubMed Central PMCID: PMCPMC1540355
  • Jawhara S, Thuru X, Standaert-Vitse A, et al. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J Infect Dis. 2008 Apr 1;197(7):972–980. PubMed PMID: 18419533.
  • Schaffer T, Muller S, Flogerzi B, et al. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn’s patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis. 2007 Nov;13(11):1339–1346. PubMed PMID: 17636567.
  • Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006 May;130(6):1764–1775. PubMed PMID: 16697740.
  • Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb;19(2):363–369. PubMed PMID: 22605661.